Danaher (NYSE:DHR – Get Rating) had its target price decreased by Robert W. Baird from $309.00 to $275.00 in a report issued on Wednesday morning, The Fly reports.

Several other research analysts have also issued reports on DHR. Credit Suisse Group lowered their price target on shares of Danaher from $300.00 to $270.00 in a report on Wednesday. Barclays lowered their price objective on shares of Danaher from $270.00 to $260.00 in a research note on Wednesday. Bank of America lowered shares of Danaher from a buy rating to a neutral rating and lowered their price objective for the company from $310.00 to $250.00 in a research note on Wednesday. Cowen lowered their price objective on shares of Danaher from $340.00 to $320.00 and set an outperform rating for the company in a research note on Wednesday, January 25th. Finally, StockNews.com assumed coverage on shares of Danaher in a research note on Thursday, March 16th. They issued a buy rating for the company. Three analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of Moderate Buy and an average price target of $293.71.

Danaher Stock Up 2.4 %

Danaher stock opened at $236.91 on Wednesday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.52 and a current ratio of 1.89. Danaher has a 52-week low of $227.00 and a 52-week high of $303.82. The firm has a 50 day moving average price of $247.57 and a two-hundred day moving average price of $257.04. The firm has a market cap of $174.82 billion, a price-to-earnings ratio of 25.53, a PEG ratio of 1.93 and a beta of 0.80.

Danaher (NYSE:DHR – Get Rating) last released its quarterly earnings results on Tuesday, April 25th. The conglomerate reported $2.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.26 by $0.10. Danaher had a net margin of 22.40% and a return on equity of 16.70%. The firm had revenue of $7.17 billion during the quarter, compared to analyst estimates of $7.06 billion. During the same quarter last year, the business earned $2.76 EPS. The company's revenue was down 6.8% compared to the same quarter last year. Equities analysts predict that Danaher will post 10.02 EPS for the current year.

Danaher Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, April 28th. Shareholders of record on Friday, March 31st were issued a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a yield of 0.46%. This is an increase from Danaher's previous quarterly dividend of $0.25. The ex-dividend date was Thursday, March 30th. Danaher's payout ratio is currently 11.64%.

Hedge Funds Weigh In On Danaher

A number of hedge funds have recently bought and sold shares of DHR. Fairfield Bush & CO. boosted its holdings in Danaher by 10.9% during the 1st quarter. Fairfield Bush & CO. now owns 4,840 shares of the conglomerate's stock worth $1,420,000 after acquiring an additional 475 shares during the last quarter. Zions Bancorporation N.A. boosted its holdings in shares of Danaher by 19.3% in the 1st quarter. Zions Bancorporation N.A. now owns 2,468 shares of the conglomerate's stock worth $724,000 after buying an additional 400 shares during the last quarter. Covestor Ltd grew its position in Danaher by 76.8% during the first quarter. Covestor Ltd now owns 495 shares of the conglomerate's stock valued at $145,000 after buying an additional 215 shares during the period. NewEdge Advisors LLC increased its holdings in Danaher by 14.1% during the first quarter. NewEdge Advisors LLC now owns 31,530 shares of the conglomerate's stock worth $9,248,000 after buying an additional 3,897 shares during the last quarter. Finally, Bridgewater Associates LP boosted its stake in Danaher by 135.9% in the first quarter. Bridgewater Associates LP now owns 35,270 shares of the conglomerate's stock valued at $10,346,000 after acquiring an additional 20,320 shares during the last quarter. 77.26% of the stock is owned by hedge funds and other institutional investors.

About Danaher

(Get Rating)

Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments: Biotechnology, Life Sciences, Diagnostics, and Environmental and Applied Solutions. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a range of tools, consumables, and services.

See Also

• Get a free copy of the StockNews.com research report on Danaher (DHR)
• How to Invest in the Top Grocery Stocks for This Year
• Array Technologies Brings Solar Flare To 2023 Earnings Forecast
• Best Bank Stocks to Invest in Ahead of Rising Interest Rates
• How to Invest in Farmland: 7 Simple Ways
• ExxonMobil Gushes To New Highs

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.